Citations

Clear

6273 citation(s) found for "To, Andrew".

Gastroblastoma of the Pylorus: A Case Report and Review of the Literature
McCammon, Nathan , Dunn, Andrew , Graham, Rondell P. , McHugh, Jonathan B. , Lamps, Laura, Bresler, Scott C. , Cole, Thomas, Rottmann, Douglas , Graham, Rondell P , Cole, Thomas

Mayo Clinic

International Journal of Surgical Pathology | February 24, 2023 | Volume: 31 | Issue: 8 | Pages: 1516-1521

10.1177/10668969231157310 | PMID 36823781 Get It

Gastroblastoma is an extremely rare biphasic tumor that typically occurs in the stomach in patients between the ages of 10 and 30. Only 16 cases have been reported previously. These tumors are important to diagnose and distinguish from more aggressive neoplasms; although numbers are small, prognosis appears excellent overall with complete excision, with only occasional metastasis and/or local recurrence. We report a case of gastroblastoma in a 26-year-old male arising from the pylorus and extending through the first and second portions of the duodenum. This is the first case to be reported from this specific location.
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study
Lee, Jessica , Currow, David C. , Phillips, Jane , McLachlan, Andrew J. , Ritchie, Megan, Fazekas, Belinda, Aggarwal, Rajesh , Seah, Davinia , Chye, Richard , Noble, Beverly, Aggarwal, Ghauri, George, Rachel, Kow, Marian, Ayoub, Chadi , Linton, Anthony , Sanderson, Christine , Mittal, Dipti, Rao, Angela , Prael, Grace , Urban, Katalin, Vandersman, Priyanka , Agar, Meera , McCaffrey, Nikki , Lovell, Melanie R , Brown, Linda , Sheehan, Caitlin

Mayo Clinic

BMJ Open | February 21, 2023 | Volume: 13 | Issue: 2 | Pages: e066125

10.1136/bmjopen-2022-066125 | PMID 36810169 Get It

Introduction Many patients experience unrelieved neuropathic cancer-related pain. Most current analgesic therapies have psychoactive side effects, lack efficacy data for this indication and have potential medication-related harms. The local anaesthetic lidocaine (lignocaine) has the potential to help manage neuropathic cancer-related pain when administered as an extended, continuous subcutaneous infusion. Data support lidocaine as a promising, safe agent in this setting, warranting further evaluation in robust, randomised controlled trials. This protocol describes the design of a pilot study to evaluate this intervention and explains the pharmacokinetic, efficacy and adverse effects evidence informing the design. Methods and analysis A mixed-methods pilot study will determine the feasibility of an international first, definitive phase III trial to evaluate the efficacy and safety of an extended continuous subcutaneous infusion of lidocaine for neuropathic cancer-related pain. This study will comprise: a phase II double-blind randomised controlled parallel-group pilot of subcutaneous infusion of lidocaine hydrochloride 10% w/v (3000 mg/30 mL) or placebo (sodium chloride 0.9%) over 72 hours for neuropathic cancer-related pain, a pharmacokinetic substudy and a qualitative substudy of patients’ and carers’ experiences. The pilot study will provide important safety data and help inform the methodology of a definitive trial, including testing proposed recruitment strategy, randomisation, outcome measures and patients’ acceptability of the methodology, as well as providing a signal of whether this area should be further investigated. Ethics and dissemination Participant safety is paramount and standardised assessments for adverse effects are built into the trial protocol. Findings will be published in a peer-reviewed journal and presented at conferences. This study will be considered suitable to progress to a phase III study if there is a completion rate where the CI includes 80% and excludes 60%. The protocol and Patient Information and Consent Form have been approved by Sydney Local Health District (Concord) Human Research Ethics Committee 2019/ETH07984 and University of Technology Sydney ETH17-1820. Trial registration number ANZCTR ACTRN12617000747325.
Lateral Epicondylitis
Marigi, Erick M. , Dancy, Malik, Alexander, Andrew , Marigi, Ian , Clark, Julian , Camp, Christopher L. , Okoroha, Kelechi R. , Marigi, Ian M , Camp, Christopher L. , Okoroha, Kelechi R , Marigi, Erick , Alexander, Andrew S , Clark, Clarence Julian , Krych, Aaron J.

Mayo Clinic

JBJS Reviews | February 17, 2023 | Volume: 11 | Issue: 2 | Pages: No page available

10.2106/jbjs.rvw.22.00170 | PMID 36800442 Get It

» Lateral epicondylitis (LE) or tennis elbow is a common cause of elbow pain in the general population, especially women in the fourth and fifth decades of life who participate in repetitive forceful movements involving the wrist and forearm. » The pathogenesis of this overuse injury is believed to start from an overload event leading to a microtear in or near the origin of the extensor carpi radialis brevis that is subsequently prone to additional injury and structural weakness over time. » Treatment of LE often begins with a wide variety of nonoperative modalities including rest, nonsteroidal anti-inflammatory drugs, bracing, and physical therapy. For recalcitrant symptoms, additional nonoperative therapies are implemented; however, there remains a lack of comparative efficacy between these adjunct treatments. » In this article, we examine the available literature regarding nonoperative management of LE and provide supplementary insight into the effectiveness of current modalities.
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Schuster, Anne L. R. , Crossnohere, Norah L. , Bachini, Melinda , Blair, Cindy K. , Carpten, John D. , Claus, Elizabeth B. , Colditz, Graham A. , Ding, Li , Drake, Bettina F. , Fields, Ryan C. , Janeway, Katherine A. , Kwan, Bethany M. , Lenz, Heinz‐Josef , Mishra, Shiraz I. , Ricker, Charité , Sussman, Andrew L. , Tiner, Jessica C. , Trent, Jeffrey M. , Verhaak, Roel G.W. , Wagle, Nikhil , Bridges, John F. P. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS), Schuster, Anne Lr , Ma, Qin , Mishra, Shiraz I , Paskett, Electra D , Rebbeck, Timothy R , Ricker, Charité , Stern, Mariana Carla , Sussman, Andrew L , Tiner, Jessica C , Trent, Jeffrey M , Verhaak, Roel Gw , Wagle, Nikhil , Willman, Cheryl , Bridges, John Fp , Colditz, Graham A , Bachini, Melinda , Paskett, Electra D. , Rebbeck, Timothy R. , Willman, Cheryl L. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS)

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 15, 2023 | Volume: 32 | Issue: 4 | Pages: 487-495

10.1158/1055-9965.epi-22-0356 | PMID 36791345 Get It

Abstract Background: Engaging diverse populations in cancer genomics research is of critical importance and is a fundamental goal of the NCI Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Established as part of the Cancer Moonshot, PE-CGS is a consortium of stakeholders including clinicians, scientists, genetic counselors, and representatives of potential study participants and their communities. Participant engagement is an ongoing, bidirectional, and mutually beneficial interaction between study participants and researchers. PE-CGS sought to set priorities in participant engagement for conducting the network's research. Methods: PE-CGS deliberatively engaged its stakeholders in the following four-phase process to set the network's research priorities in participant engagement: (i) a brainstorming exercise to elicit potential priorities; (ii) a 2-day virtual meeting to discuss priorities; (iii) recommendations from the PE-CGS External Advisory Panel to refine priorities; and (iv) a virtual meeting to set priorities. Results: Nearly 150 PE-CGS stakeholders engaged in the process. Five priorities were set: (i) tailor education and communication materials for participants throughout the research process; (ii) identify measures of participant engagement; (iii) identify optimal participant engagement strategies; (iv) understand cancer disparities in the context of cancer genomics research; and (v) personalize the return of genomics findings to participants. Conclusions: PE-CGS is pursuing these priorities to meaningfully engage diverse and underrepresented patients with cancer and posttreatment cancer survivors as participants in cancer genomics research and, subsequently, generate new discoveries. Impact: Data from PE-CGS will be shared with the broader scientific community in a manner consistent with participant informed consent and community agreement.
Cover Image, Volume 6, Issue 2
Giorgakis, Emmanouil , Wells, Allison, Balogh, Julius , Krinock, Derek , Burdine, Lyle , Singer, Andrew L., Mathur, Amit K. , Giorgakis, Emmanouil , Balogh, Julius , Ivanics, Tommy , Wallace, David , Hardgrave, Hailey , Klutts, Garrett N.

Mayo Clinic

Health Science Reports | February 15, 2023 | Volume: 6 | Issue: 2 | Pages: No page available

10.1002/hsr2.1125 Get It

Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers
Sugier, Pierre‐Emmanuel , Lucotte, Elise A. , Domenighetti, Cloé , Law, Matthew H. , Iles, Mark M. , Brown, Kevin M. , McKay, James , Hung, Rayjean J., Karimi, Mojgan, Bacq‐Daian, Delphine, Boland, Anne , Kesminiene, Ausrele , Vathaire, Florent de , Guénel, Pascal , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Hung, Rayjean J. , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Zimprich, Alexander , Lang, Anthony E , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Deutschländer, Angela B , Hadjigeorgiou, Georges M., Stefanis, Leonidas , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Hung, Rayjean J , Puschmann, Andreas , Guénel, Pascal , Law, Matthew H , Iles, Mark M , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Amos, Christopher I. , Olaso, Robert , Deleuze, Jean‐François , Lesueur, Fabienne , Ostroumova, Evgenia , Schulte, Claudia , Bobbili, Dheeraj Reddy , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Dardiotis, Efthimios , Simitsi, Athina‐Maria , Valente, Enza Maria , Zecchinelli, Anna , Pezzoli, Gianni , Gagliardi, Monica , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Farrer, Matthew J. , Truong, Thérèse , Elbaz, Alexis

Mayo Clinic

Movement Disorders | February 14, 2023 | Volume: 38 | Issue: 4 | Pages: 604-615

10.1002/mds.29337 | PMID 36788297 Get It

Abstract Background Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties. Objective We used results from genome‐wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors. Methods We used individual data for participants of European ancestry from the Courage‐PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta‐Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa, using cross‐phenotypes polygenic risk score (PRS) analyses. Results We confirmed a previously reported positive genetic correlation of PD with melanoma (G corr = 0.16 [0.04; 0.28]) and reported an additional significant positive correlation of PD with prostate cancer (G corr = 0.11 [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the NSF gene (17q21.31). Conclusions We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna , Andrulis, Irene L. , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Daly, Mary B., Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, Johnson, Nichola , Kristensen, Vessela N. , Lindblom, Annika , Mannermaa, Arto , Mavroudis, Dimitrios, Nevelsteen, Ines, Neven, Patrick , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Phillips, Kelly‐Anne , Plaseska-Karanfilska, Dijana, Rack, Brigitte , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Adank, Muriel A. , Hooning, Maartje J. , Eccles, Diana , Plaseska‐Karanfilska, Dijana , Eccles, Diana , Evans, D Gareth , García-Closas, Montserrat , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Schreurs, Maartje A. C. , Anton‐Culver, Hoda , Augustinsson, Annelie , Behrens, Sabine , Bojesen, Stig E. , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Graßmann, Felix , Hartikainen, Jaana M. , Hopper, John L. , Houlston, Richard S. , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Jones, Michael E. , Kurian, Allison W. , Lambrechts, Diether , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mulligan, Anna Marie , Muranen, Taru , Nevanlinna, Heli , Newman, William G. , Olshan, Andrew F. , Peterlongo, Paolo , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Romero, Atocha , Saloustros, Emmanouil , Scott, Christopher, Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Pharoah, Paul D.P. , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

No container title available | February 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2569372/v1 | PMID 36824750 Get It

Abstract Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09–1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words)
Physiological Age by Artificial Intelligence–Enhanced Electrocardiograms as a Novel Risk Factor of Mortality in Kidney Transplant Candidates
Lorenz, Elizabeth C. , Johnson, Bradley K. , Petterson, Tanya M. , Kremers, Walter K. , Winkelmayer­, Wolfgang C. , Baez‐Suarez, Abraham, Lopez‐Jimenez, Francisco, Friedman, Paul A. , Kennedy, Cassie C. , Zaniletti, Isabella, Baez-Suarez, Abraham, Kennedy, Cassie C , Kremers, Walter K , Zaniletti, Isabella , Schinstock, Carrie A. , Amer, Hatem , Cheville, Andrea , LeBrasseur, Nathan K. , Navaneethan, Sankar Dass , Attia, Zachi I. , López-Jiménez, Francisco , Rule, Andrew D.

Mayo Clinic

Transplantation | February 13, 2023 | Volume: 107 | Issue: 6 | Pages: 1365-1372

10.1097/tp.0000000000004504 | PMID 36780487 Get It

Background. Mortality risk assessment before kidney transplantation (KT) is imperfect. An emerging risk factor for death in nontransplant populations is physiological age as determined by the application of artificial intelligence to the electrocardiogram (ECG). The aim of this study was to examine the relationship between ECG age and KT waitlist mortality. Methods. We applied a previously developed convolutional neural network to the ECGs of KT candidates evaluated 2014 to 2019 to determine ECG age. We used a Cox proportional hazard model to examine whether ECG age was associated with waitlist mortality. Results. Of the 2183 patients evaluated, 59.1% were male, 81.4% were white, and 11.4% died during follow-up. Mean ECG age was 59.0 ± 12.0 y and mean chronological age at ECG was 53.3 ± 13.6 y. After adjusting for chronological age, comorbidities, and other characteristics associated with mortality, each increase in ECG age of >10 y than the average ECG age for patients of a similar chronological age was associated with an increase in mortality risk (hazard ratio 3.59 per 10-y increase; 95% confidence interval, 2.06-5.72; P < 0.0001). Conclusions. ECG age is a risk factor for KT waitlist mortality. Determining ECG age through artificial intelligence may help guide risk-benefit assessment when evaluating candidates for KT.
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, Leslie , Kaunitz, Andrew M., Hayes, Sharonne N. , Lau, Emily S. , Pristera, Nicole , Scott, Nandita S. , Shifren, Jan L. , Shufelt, Chrisandra , Stuenkel, Cynthia A. , Hayes, Sharonne N , Lau, Emily S , Scott, Nandita , Shufelt, Chrisandra L , Lindley, Kathryn J , Faubion, Stephanie S.

Mayo Clinic

Circulation | February 13, 2023 | Volume: 147 | Issue: 7 | Pages: 597-610

10.1161/circulationaha.122.061559 | PMID 36780393 Get It

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.